Dicerna Pharmaceuticals reported $-18821000 in EBITDA for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Acceleron Pharma XLRN:US $ -69.47M 6.84M
Alnylam Pharmaceuticals ALNY:US $ -169.89M 35.54M
Amgen AMGN:US $ 3228M 40M
Arrowhead Research ARWR:US $ -62379000 32.51M
Biogen BIIB:US $ 991.8M 155.8M
Bluebird Bio BLUE:US $ -190.8M 44.05M
Dicerna Pharmaceuticals DRNA:US $ -18.82M 19.76M
Exelixis EXEL:US $ 56.42M 70.25M
Gilead Sciences GILD:US $ 4370M 1605M
GlaxoSmithKline GSK:LN 3660M 1034M
Intercept Pharmaceuticals ICPT:US $ -5.41M 6.8M
Karyopharm Therapeutics KPTI:US $ -43626000 5.19M
Macrogenics MGNX:US $ -50191000 12.69M
Mirati Therapeutics MRTX:US $ -78.98M 84.79M
Pfizer PFE:US $ 10235M 2245M
Regeneron Pharmaceuticals REGN:US $ 1920.4M 1497.9M
Ultragenyx Pharmaceutical RARE:US $ -86.61M 6.96M